Alteration in immune function in patients with fatty liver disease
作者机构：Department of SurgeryRutgers Robert Wood Johnson Medical SchoolNew BrunswickNJ 08901USA Division of Surgical OncologyDepartment of SurgeryThe Ohio State University Wexner Medical CenterColumbusOH 43210USA
出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)
年 卷 期：2022年第8卷第1期
页 面：363-375页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Non-alcoholic steatohepatitis nonalcoholic fatty liver disease steatohepatitis immunology hepatocellular carcinoma
摘 要：Nonalcoholic fatty liver disease(NAFLD)is a disease spectrum that spans simple steatosis,fibrosis,and ultimately cirrhosis,and is a leading cause of chronic liver disease *** severe variant of NAFLD,non-alcoholic steatohepatitis(NASH),is characterized by triglyceride accumulation within hepatocytes and the subsequent inflammatory pathway activation,ultimately progressing to cirrhosis in 10%-20%of *** is a known major risk factor for the development of hepatocellular carcinoma(HCC),and there is emerging data demonstrating the impact of NASH on immune subsets and the tumor microenvironment that may influence therapeutic *** review describes the various ways in which the immune system is altered in patients with *** innate immune system in NASH shows alterations in dendritic and Kupffer cells,impaired cytotoxicity of Natural Killer cells,and an accumulation of ***,there is emerging evidence emphasizing the role of the adaptive immune system in the development and progression of NASH,seen in the alteration of B-cells,T-cells,and NKT *** to the complex interplay of the immune system in NAFLD/NASH and its progression to HCC,many current treatments focus on targeting immune cells for HCC ***,immune checkpoint inhibitors such as atezolizumab and bevacizumab have been approved as first-line therapy for unresectable *** an emerging field of research,further studies and clinical trials are needed to understand the complex interface of NASH,HCC and the immune response.
维普期刊数据库